DOCSLIB.ORG

An Assessment of Behavioral Tests to Detect Impaired Drivers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

December 1981 DOT HS-806.211 Final Report 21 An Assessment of us oep m ern <9Tranooranonf Behavioral Tests to AdwWrAs"ahm Detect Impaired Drivers K. J. Snapper D. A. Seaver J. P. Schwartz. Decision Science Consortium, Inc. 7700 Leesburg Pike, Suite 421 Falls Church, Virginia 22043 Contract No. DTNH 22-80-C-07565 Contract Amount $67,766 This document is available to the U.S. public through the National Technical information Service. Springfield, Virginia 22161 Technical Report Documentation Page­ . Report Me. 2. Government Acc.....n No. 3. Rec.p.ent's C.t.l.q No. DOT-HS-806 211 . Title end Svbtitl. S. Report O.,. December 1981 AN ASSESSMENT OF BEHAVIORAL TESTS TO DETECT 6. Perlora.ng o.geniset.on Code IMPAIRED DRIVERS . Perfe.n..i.q dgon.aer.on Report N.. 7. Artb.rt s) K. J. Snapper, D. A. Seaver, J. P. Schwartz* 81-11 9. Performing org.ntsett.n Nome end Address Ia. w.,b Unto Me. (TRAIS) Decision Science Consortium, Inc. 11. Contract or Great No. 7700 Leesburg Pike, Suite 421 DTNH22-80-C-07565 Falls Church, Virginia 22043 13. Type *I Roper# end Petted Covered 12. Sponsoring Agency Nome end Address Final Report U.S. Department of Transportation August 1980 - December 1981 National Highway and Traffic Safety Administration Problem Behavior Research Division 14. Sponsoring Agency Cod. Washington, D.C. 20590 15. Supplementary Notes .*With a contribution by Elliot R. Levine, Esq. 16. Abstract ' This study was conducted to assess the feasibility and practicality of road­ side behavioral tests for driving impairment. Such tests are seen as complementary to chemical tests of blood drug concentration. Methodological issues in the use of behavioral tests are identified and discussed focusing specifically on the validity of behavioral measures. It is argued that if validity is defined as pre­ dicting accidents, it will always be low for any behavioral test as well as for chemical tests because of the inherent unpredictability of accidents. The rationale for using behavioral tests, particularly a battery of behavioral tests, to detect driving impairment is, then, that such tests can measure the level of behavioral skills involved in driving. In order to evaluate various behavioral tests, a large literature was reviewed to identify potential tests and any previous studies of them. Criteria for evaluating the tests were developed, including validity, reliability, ease of operational use, safety, and diagnosticity. Each of 54 tests were scored on each criterion, and criteria were weighted by their relative importance from the perspectives of researchers and users to produce an overall index of the feasibility of each test. Tests that were rated highly include visual acuity, finger-to-finger, finger-to-nose, and romberg (and modified romberg). An analysis was also performed of legal issues relating to the use of roadside be­ havioral tests. Such tests appear to have useful status as evidence (primarily circumstantial), and probably can be used without a need for expert witnesses. 17. Key words It. Distribution Statement Legal Issues Test Validity Document is available to the public Behavioral Tests Test Reliability through the National Technical Inf Driving Impairment Test Safety oration Service, Springfield, Virginia Human POperationalPerformanceer Use of Drug Effects Test 22161 20. S.ctrrity Cl.ssil. (.f this peg.) 21. No. of Pages 1 22. Pr's. 19. S.a► rity Cfo.e.f. 161 this report) 122 I Unclassified I Unclassified Fonts DOT F 1700.7 (9-72) Reproduction of form and completed page is authorized METRIC CONVERSION FACTORS Approtinlsfo Cowv./ti00s to Metric Measures • Approximate Convections flow Motlit Message$ if••bel Moo was Rases Mel/ISl, by To flee Symbol fNwb.l W►sl► yen Olson M.hIl1T ►T To line f/w► sl in aUNGTH LENGTH In's aIU.s•Iw. 0.04 Inches In a. e.MineNws ^.4 loc1•. in a .•Iw. in Inches •2.e c.nliw.l.rs cm 2J bs1 it sw..s 1.1 Ww4s N Met 3$ c..a.svla. c•n w I'd lis bilw.•Iws daises f0 Weals 0.9 Mors •. 0.o .d .11 wills 1.0 ►illn•tws M AREA AREA w cm, glrwe csnlas.lws 6.10 ga.w0 b•Ixl.e Ue Is► wows b5d.os 9.6 *"we cw7 ►wstrs cw:. w q.we .•5. 5 1.2 sr-0 ►e.1s to so.". Mel o." "Woo is1515 w) Nt WE e^a.ws tllwsst.w 0.4 q+..555. his ow.i.. Winds 4.4 sows .•Iws .r we so Mclwe. 110.1100 a 1 2.0 owes nit owing .dlcs 2.4 4 0 Winnows bunt acme 0.4 becwns he * MASS [wel2ki) MASS Iwd tlt 0 7.w 0.en er•.. .4 « ounces t0 p.4ss O be all 8-8 2.1 /arid. w • rye ..4$ lllp sM• 4 ► 1 uses 11000 ll 1.1 dwl sons 515.4/ 1.411 5.f wawa 1 ► 12000 M) VOLUME votuME .dlll l.lw. O.q now era.. 0 .5 IM Iss.pwll • e5illllllsr. ell 004 willitho•. wt 1 films piolm f►y ..N..pw.s le qr./s N.I II.i1 *-coo in 5oi151111w/ .1d 1 Aiwa 1..4 M t c.p. 0.14 "woo 1 1 111... 0.14 Os11w.s p1 its M Idwls 0.41 111ws 1 w1 cibk •wws 3$ Mic bd ea. 0.1$ 11S1 1 w) colic Insist . 1.2 culik Wants M yd 90=6Ss 3.0 Ill... 1 hx cubic #401 0.03 cubic d•Iws f11 cubic Wwi% O.2$ cubic daicss w3, TEMPERATURE Iococl) TEMPERATURE loc'cl) .c c.l.l.. $/5 511.s.s /.ArewheN eape*Iwo .ed 211 I•a•i•a^1.•e Idss.la.ll 11111s11w Celsius 'C II M.paa..Me .dwuc5is IM^.amowe 2t1 of 21 994 at -40 0 1 40 so t • Ito 100 t00 1 • 1 w • 1... r..• 1$vl. I...Mae.....r .....e...•...a..1...•• A`1w.I d Sm.....•. Nit.l^....sll. 7.4, -40 -t0 Y0 00 NO 00 0O ^C y...../ h.,..s ...I.1......•.. N... s5.M. f0 (anal.. M.. CI),51.1.4. .c 11 METRIC CONVERSION FACTORS * TABLE OF CONTENTS Page 1.0 INTRODUCTION AND BACKGROUND ................................... 1-1 1.1 Legislative Mandate for Study ............................ 1-1 1.2 Technical Problems in Developing Tests of impairment ..... 1-2 1.2.1 Non-Invasive Chemical Tests ....................... 1-3 1.2.2 Ambiguity of Blood Drug Concentration Analyses .... 1-3 1.2.3 Defining Impairment Threshold in Terms of BDC ..... 1-4 1.2.4 Specificity of Behavioral Tests ................... 1-4 1.2.5 Practicability .................................... 1-5 1.3 Scope of Present Study: Assessment of Behavioral Test Procedures .......................................... 1-5 2.0 IMPAIRMENT MEASURES: METHODOLOGICAL ISSUES IN INDEX CONSTRUCTION, EVALUATION, AND VALIDATION ...................... 2-1 2.1 The Criterion Problem .................................... 2-i 2.2 Operational Criteria ..................................... 2-3 2.2.1 Traffic Accidents as an Operational Criterion of Impairment ..................................... 2-3 2.2.2 A Behavioral Test as an Operational Criterion of Impairment ..................................... 2-5 2.2.3 Driving-Like Tasks as an Operational Criterion of Impairment ..................................... 2-7 2.2.4 BDC as an Operational Criterion of impairment 2-9 2.3 Some Tenets Regarding Development of Measures of Impairment ............................................... 2-11 2.4 Procedures for the Development of a Behavioral Index of Impairment ............................................ 2-13 2.5 Validation of a Behavioral Index of Impairment ........... 2-18 2.6 Criteria for Evaluating Indices of Impairment ............ 2-18 3.0 CRITERIA, TESTS, AND EVALUATION ............................... 3-1 3.1 Evaluation Approach and Methodology ...................... 3-2 3.2 Development of Evaluative Criteria ....................... 3-5 3.3 identification of Behavioral Tests ....................... 3-10 3.4 Evaluation of Behavioral Tests ........................... 3-27 3.4.1 Importance Weights for Criteria ................... 3-27 3.4.2 Comparative Assessments of Tests .................. 3-32 3.5 Quantitative Evaluation Results .......................... 3-42 4.0 DISCUSSION AND RECOMMENDATIONS ................................ 4-1 5.0 REFERENCES ...................................................... 5-1 iii TABLE OF CONTENTS (continued) Page APPENDIX: ANALYSIS OF LEGAL ISSUES (Elliot R. Levine, Esq.) ....... .A-1 A..1 Summary ................................................. A-1 A.1.1­ Legal Relevance of Behavioral Tests ..... ....s. A-1 A.1.2­ Evidential Role of Behavioral Tests .............. A-1• A.1.3­ Police Officers.as Witnesses ...................... A-1 A.1.4­ Constitutional Rights .............................. A-2 A.1.5­ Due Process ................................. A-3 A.1.6­ Indigent Defendants A-3 A.2 Legal Relevance of Field Behavior Tests­ A-3 A.3 Behavioral Tests as Evidence ............................ A-4 A.3.1­ Difference Between Circumstantial and Direct Evidence ..................... .......... A-4 A.3.2­ Behavioral Tests are Circumstantial Evidence .......................................... A-4 A.3.3­ Sufficiency of Circumstantial Evidence ........... A-5 A.3.4­ Requirements for Direct Evidence A-5 A.3.5­ Effects of Distinction Between "Narcotic" and Other Drugs .................................. A-8 A.4 Police Officers as Witnesses ............................ A-9 A.4.1­ Police Officers as Non-Experts ................... A-9 A.4.2­ Constraints on Testimony .......................... A-10 A.5 Constitutional Rights and Behavioral Tests .............. A-11 A.5.1­ Right to Remain Silent ............................ A-il A.5.2 Use of Force ..................................... A=12 A.5.3­ Behavioral Tests Without Counsel A-13 A.5.4­ Refusal to Submit to Behavioral Test may be Used Against Defendant ........................ A-13 A.5.5­ Implied Consent and Behavioral Tests .............. A-13 A.6 Blood Tests in Addition to Behavioral Tests ............. A-14 A.7 Rights of Indigents ..................................... A-17 A.8 Conclusion ........................................ A-18 iv 1.0 INTRODUCTION AND BACKGROUND Drivers who are unable to operate their vehicles safely should not drive, but there is considerable controversy about how best to detect driver impairment.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis

    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
  • Treating Mesothelioma: Reviewing Multiple Treatment Modalities” Or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma”

    Treating Mesothelioma: Reviewing Multiple Treatment Modalities” Or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma”

    Evidence-Based Practice Group Answers to Clinical Questions “Treating Mesothelioma: Reviewing Multiple Treatment Modalities” or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma” A Rapid Systematic Review By WorkSafeBC Evidence-Based Practice Group Dr. Craig Martin Manager, Clinical Services Chair, Evidence-Based Practice Group January 2016 Clinical Services – Worker and Employer Services Treating Mesothelioma: Reviewing Multiple Treatment Modalities i About this report “Treating Mesothelioma: Reviewing Multiple Treatment Modalities” or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma” Published: January 2016 About the Evidence-Based Practice Group The Evidence-Based Practice Group was established to address the many medical and policy issues that WorkSafeBC officers deal with on a regular basis. Members apply established techniques of critical appraisal and evidence-based review of topics solicited from both WorkSafeBC staff and other interested parties such as surgeons, medical specialists, and rehabilitation providers. Suggested Citation WorkSafeBC Evidence-Based Practice Group, Martin CW. Treating Mesothelioma: Reviewing Multiple Treatment Modalities” or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma. Richmond, BC: WorksafeBC Evidence-Based Practice Group; January 2016. Contact Information Evidence-Based Practice Group WorkSafeBC PO Box 5350 Stn Terminal Vancouver BC V6B 5L5 Email [email protected] Phone 604 279-7417 Toll-free 1 888 967-5377 ext 7417 View other systematic reviews by the EBPG online at: http://worksafebc.com/evidence WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 1 Objective To determine whether there is evidence on the efficacy or effectiveness and safety of the treatment modalities for mesothelioma offered at some centres in the United States.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
  • (12) United States Patent (Lo) Patent No.: �US 8,480,637 B2

    (12) United States Patent (Lo) Patent No.: US 8,480,637 B2

    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al

    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX

  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs

    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid